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Background: The vesicular B0AT3 transporter (SLC6A17), one of the members of the SLC6 family, is a transporter for
neutral amino acids and is exclusively expressed in brain. Here we provide a comprehensive expression profile of
B0AT3 in mouse brain using in situ hybridization and immunohistochemistry.
Results: We confirmed previous expression data from rat brain and used a novel custom made antibody to obtain
detailed co-labelling with several cell type specific markers. B0AT3 was highly expressed in both inhibitory and
excitatory neurons. The B0AT3 expression was highly overlapping with those of vesicular glutamate transporter 2
(VGLUT2) and vesicular glutamate transporter 1 (VGLUT1). We also show here that Slc6a17mRNA is up-regulated in
animals subjected to short term food deprivation as well as animals treated with the serotonin reuptake inhibitor
fluoxetine and the dopamine/noradrenaline reuptake inhibitor bupropion.
Conclusions: This suggests that the B0AT3 transporter have a role in regulation of monoaminergic as well as
glutamatergic synapses.Background
The SLC6 family of proteins consists of 19 functional
members and four pseudogenes in human [1] and many
of the proteins belonging to the this family are presynaptic
reuptake transporters. The major substrates are the
monoamine neurotransmitters noradrenaline (NA), dopa-
mine (DA) and serotonin (5-HT), amino acids including
γ-aminobutyric acid (GABA) as well as other neutral
amino acids, and osmolytes such as taurine, creatine and
betaine [2,3]. Transporters from the SLC6 family are sec-
ondary active transporters dependent on electrochemical
Na+ or H+gradients to drive the transport. Na+ gradients
are maintained over the plasma membrane of all cells,
while H+ gradients are maintained over internal mem-
branes such as synaptic vesicles. Already in the beginning
of the 1990s, the sequence of the SLC6A17 transporter
was determined by sequencing cDNA from mammalian
sources and was shown to have high expression exclu-
sively in the CNS. At that time, the substrate of transport
was not known [4-6]. Phylogenetic analysis of the whole* Correspondence: Robert.Fredriksson@neuro.uu.se
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reproduction in any medium, provided the orSLC6 family originally classified the members into four
subgroups termed GABA, monoamine, amino acid, and
the orphans [1,7]. The orphan subgroup is now known to
contain transporters for neutral amino acids and is hence
renamed the amino acid transporter group II [2].
SLC6A17 is most similar to SLC6A15 (B0AT2) regarding
sequence identities [1,2,8], mRNA expression [9], as well
as substrate profile [8,10-12]. The protein product of the
SLC6A17 gene is termed B0AT3 [12], which will be the
notation used further in this paper. Interestingly, the main
difference between B0AT2 and B0AT3 is the subcellular
localization, with B0AT2 being localized at the plasma
membrane (unpublished data), while B0AT3 is known to
be expressed on vesicles [11-14].
It was recently shown by two independent groups that
B0AT3 acts as a transporter of a broad range of neutral
amino acids with affinity for proline, leucine and glycine,
alanine and glutamine [11,12]. However, the preference
for ion coupling of B0AT3 is arguable as one study showed
that B0AT3 is Na+-dependent and Cl--independent
[12], while another study showed B0AT3 not to be
Na+dependent but rather dependent on the H+gradi-
ent maintained by the vacuolar-type H+-ATPase [11].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2202/14/54In situ hybridization and immunohistochemistry stud-
ies, performed mainly on rat tissues, have revealed that
Slc6a17 mRNA as well as the B0AT3 protein is widely dis-
tributed throughout the CNS. The transporter is found
exclusively in axon terminals of most glutamatergic neu-
rons and in a sub-population of GABAergic neurons in
embryonic [15] as well as adult rat brain [4,9,13,14,16-18].
A similar pattern have been suggested also in mouse [19]
and human [20], although no comprehensive mapping
have been performed in these species. The physiological
function of B0AT3 (SLC6A17) is still unknown, although
several alternatives have been suggested [11,12,14,19].
Many of the amino acid transporters in the SLC6 family
are known to play important roles in several pathological
conditions including obesity (SLC6A14) [21-23] and major
depression (SLC6A15) [24]. Providing that B0AT3 has a
very similar substrate profile as B0AT2, but with unique
expression in the synapses, we hypothesized that B0AT3
could also play a role in depression and in the action of
antidepressant drugs. Given the proposed synaptic
localization, B0AT3 could possibly play a role in synaptic
remodeling, a process important in the long term action
of antidepressant drugs [25] as well as in other functions
of the nervous system.
In this context, we challenged the serotonin and the
dopamine/noradrenaline systems with drugs (fluoxetine
and bupropione, respectively) and studied effects on ex-
pression of Slc6a17 and Slc6a15 mRNA in various brain
regions. Fluoxetine is an antidepressant drug of theFigure 1 High mRNA expression of Slc6a17 in rat CNS and low expres
with standard deviations displaying the rat Slc6a17 expression (% ± SD%) re
expression in brain, spinal cord and epididymis, and low or almost no expr
eight rat brain cross sections and the picture with the sagittal mouse brainselective serotonin reuptake inhibitor (SSRI) class, clinic-
ally used to treat depressive disorders, while bupropion is
a noradrenaline and dopamine reuptake inhibitor. Bupro-
pion is used in treatment of depression as well as a smok-
ing cessation aid, due to its actions on the reward system
in the brain. We also studied Slc6a17 and Slc6a15 trans-
porters in terms of their involvement in food intake con-
trol in a model of acute food deprivation and in a model
for chronic food restriction, using a validated quantitative
real-time PCR method. We show here that Slc6a17mRNA
is strongly regulated under these conditions. Additionally,
we provide a complete view of B0AT3 (Slc6a17) expres-
sion in the central nervous system of mouse. We accom-
plished this with in situ hybridization on mouse brain and
spinal cord, confirming previously shown gene expression
of Slc6a17. We also made polyclonal B0AT3 antibody and
used immunohistochemistry to study endogenous protein
expression of B0AT3 in mouse nervous system, to identify
specific cell types expressing the B0AT3 transporter.
Results
High Slc6a17 gene expression in rat CNS
Expression analysis of Slc6a17 in CNS and peripheral tis-
sues (Figure 1) showed widespread, multifocal expression
in the rat CNS and low or almost no expression in periph-
eral tissues. The relative expression of Slc6a17 was highest
in hindbrain (100 ± 29), brain slice II (71 ± 21) and brain
slice VII (67 ± 3). Slc6a17mRNA was also highly expressed
in the other tissues with the following relative expression;sion in periphery. Real-time PCR data visualized as column charts
lative to maximum (fold decrease). Slc6a17 showed high cDNA
ession in the other peripheral tissues. The abbreviations I–VIII indicates
indicates the Bregma coordinates for these sections.
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http://www.biomedcentral.com/1471-2202/14/54brain slice VI (47 ± 10), brain slice V (46 ± 19), brain slice I
(44 ± 5), brain slice IV (43 ± 4), brain slice III (22 ± 2),
cerebellum (20 ± 5), spinal cord (15 ± 2), brain slice VIII
(15 ± 3), brain stem (9 ± 1), epididymis (5 ± 0) and hypo-
thalamus (5 ± 1). Relative expression below 2% was seen
in skeletal muscle, intestine, liver and eye, while really low
expression below 1% was seen in the other peripheral
tissues (Figure 1).
Expression of Slc6a17 mRNA in mouse POMC and NPY
neurons, and in both excitatory and inhibitory neurons
Double in situ hybridization was used to identify cell types
expressing Slc6a17 in mouse brain (Figure 2A-D).
Proopiomelanocortin (POMC) and neuropeptide Y (NPY)
are expressed in adjacent subpopulations of arcuate nu-
cleus neurons (Arc), and are known to be involved in the
regulation of food intake [26]. Our experiments demon-
strated that Slc6a17 mRNA co-localized with POMC and
other neurons in Arc in the hypothalamus (Figure 2A).
The Slc6a17 mRNA also co-localized with NPY and was
also found in other neurons in Arc (Figure 2B). Slc6a17
showed overlapping mRNA expression with glutaminase,
but was also found in glutaminase negative neurons in
cerebral cortex (Figure 2C). Slc6a17 also localized to
Gad67 expressing neurons as well as other neurons in cor-
tex (Figure 2D). These results collectively show that
Slc6a17 is expressed in both excitatory and inhibitory neu-
rons in the brain. Combined in situ hybridization with im-
munohistochemistry was used on mouse spinal cord
sections to investigate if Slc6a17 was expressed in GFAP
positive (glia) cells [27] (Figure 2E). The Slc6a17 mRNA
expression was located to interneurons in the grey matter
and in subsets of cholinergic motor neurons in the upper
lumbar vertebrae L2. Co-staining with Slc6a17 mRNA
and the GFAP antibody did not overlap in spinal cord,
suggesting no Slc6a17 expression in astrocytes.
Abundant mRNA expression of Slc6a17 in mouse brain
and spinal cord
In situ hybridization with a probe against Slc6a17 was
used to evaluate expression of Slc6a17 in mouse brain
and spinal cord (Figure 3, Additional file 1: Table S1).
The DIG-labeled antisense Slc6a17 probe was 285 bp
long and directed against the last coding exon of the
gene. We confirmed high levels of Slc6a17 expression in
gray but not in the white matter in the brain. High
mRNA expression was seen in hippocampus, cerebellum,
cerebral cortex, thalamus, amygdala, pons, while low ex-
pression was seen in basal ganglia and spinal cord. Slc6a17
showed expression in the strias of CPu (Figure 3A and G)
and in NAcc. Staining was detected in septum (Figure 3B
and H), hippocampal GrDG and Py (Figure 3C and I), all
layers of cerebral cortex except layer 1 (Figure 3C and J),
DMH, VMH, LH and Arc in hypothalamus (Figure 3Dand K), BLA and BLV in amygdala (Figure 3D and L), LC
and Bar in pons, and in the Purkinje layer of cells in cere-
bellum (Figure 3E and M). In addition, Slc6a17 was also
highly expressed in Piriform cortex. Widespread Slc6a17
mRNA expression was detected in the spinal cord, where
the gene was detected in subsets of somatic motor neu-
rons and in interneurons (Figure 3F and N).
Specificity of the B0AT3 antibody
We generated rabbit polyclonal B0AT3 antibody against
an epitope in the N-terminus, to verify the expression
obtained with the commercially available antibody. We
used immunohistochemistry to document the epitope
specificity of the antibody by co-labeling it with the
commercially available monoclonal mouse-B0AT3 anti-
body (Additional file 1: Figure S1). The immunohisto-
chemistry with the B0AT3 antibodies showed highly
overlapping expression in mouse CNS, with one excep-
tion. The commercially available B0AT3 antibody gave
staining within some cells in spinal cord which was not
seen for the custom-made polyclonal B0AT3 antibody.
This could be due to the fact that different epitopes were
used to generate the antibodies and that, the epitope we
used is not exposed in these specific cells. It could also be
due to low expression of B0AT3 in these cells and that the
mouse antibody has higher sensitivity. Another possibility
is that the commercial antibody is slightly less specific and
hence detects another protein in these cells. This experi-
ment verifies the specificity of both antibodies.
Mouse CNS localization of B0AT3 protein in the cell body,
axon and synapses of inhibitory and excitatory neurons
A number of neuronal markers were used to visualize the
neuronal expression of the B0AT3 transporter (Figures 4
and 5). Highly overlapping expression was seen for B0AT3
and the neuronal marker (NeuN) [30] (Figure 4A). The
B0AT3 expression was localized to the cell body and in
the axon of neurons in cerebral cortex and also in other
areas. The microtubule-associated protein 2 (MAP2) [31]
and B0AT3 co-localized in the cell body of neurons in the
cerebral cortex and other areas in the brain (Figure 4B).
Gad67 [32] was used to show expression of B0AT3 in
GABAergic neurons (Figure 4C). We also used the vesicu-
lar inhibitory amino acid transporter VIAAT (VGAT), a
marker of synaptic vesicles in GABAergic neurons and in
sets of glycinergic neurons [33], and synaptophysin, a
generally expressed presynaptic vesicle glycoprotein
[34], to investigate the vesicular localization of B0AT3.
Co-localization of B0AT3 and VIAAT indicated highly
overlapping expression in inhibitory synapses in hippo-
campus, and similar co-localization was also found in
other areas of the brain and in spinal cord (Figure 4D).
B0AT3 and synaptophysin immunoreactivity extensively
overlapped in grey matter in spinal cord, and similar
Figure 2 Expression of Slc6a17mRNA in POMC, NPY, excitatory and inhibitory neurons. Double in situ hybridization (A-D) and combined in
situ hybridization/immunohistochemistry (E) using Slc6a17 probe for co-localization of Slc6a17mRNA and markers in mouse brain and spinal cord are
shown in this figure. The cell nucleus marker DAPI was stained in blue. (A) Co-localization of Slc6a17mRNA (red) and POMC-mRNA (dark blue) in
hypothalamus close to the third ventricle (Bregma −2.18). (B) Overlapping expression of Slc6a17 (red) mRNA and NPY labeled neurons (dark blue) in
arcuate nucleus in hypothalamus (Bregma −2.06). (C) Co-localization of Slc6a17mRNA (red) and glutaminase-mRNA (brown) in excitatory neurons in
cerebral cortex (Bregma −1.58). (D) Co-expression of Slc6a17mRNA (red) and Gad67-mRNA (brown) in inhibitory neurons in cerebral cortex (Bregma −1.58).
(E) No co-localization between Slc6a17mRNA (brown) and the GFAP protein (green) expression in spinal cord (L2). All pictures were taken with 20x
objective using cryo sections (A and B) and paraffin embedded sections (C-E). Bregma coordinates are according to Franklin and Paxinos 2007 [28].
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Figure 3 Slc6a17mRNA expression in mouse CNS. In situ hybridization on free floating sections using 1 μg probe/ml of DIG-labeled (blue
staining) mouse Slc6a17 probe. Coronal mouse brain and spinal cord sections, visualized as over view (A-F) and close up (G-N) pictures. Brain
abbreviations; caudate putamen (striatum) (CPu), nucleus accumbens, core (NAccC), lateral septal nucleus, lateral ventricle (LV), indusium griseum
(IG), dorsal part (LSD), lateral septal nucleus, intermediate part (LSI), lateral septal nucleus, ventral part (LSV), septofimbrial nucleus (SFi), bed
nucleus of the striater minalis (BNST), septohypothalamic nucleus (SHy), pyramidal cell layer of the hippocampus (Py), granule cell layer of the
dentate gyrus (GrDG), medial habenular nucleus (MHb), lateral habenular nucleus (LHb), mediodorsal thalamic nucleus (MD), laterodorsal thalamic
nucleus, dorsomedial part (LDDM), laterodorsal thalamic nucleus, ventrolateral part (LDVL), central medial thalamic nucleus (CM), ventromedial
thalamic nucleus (VM), ventrolateral thalamic nucleus (VL), ventral posteromedial thalamic nucleus (VPM), reticular thalamic nucleus (Rt), layers of
cortex (1–6), third ventricle (3 V), dorsomedial hypothalamic nucleus (DMH), ventromedial hypothalamic nucleus, dorsomedial part (VMHDM),
ventromedial hypothalamic nucleus, central part (VMHC), ventromedial hypothalamic nucleus, ventrolateral part (VMHVL), lateral hypothalamus
(LH), arcuate hypothalamic nucleus (Arc), lateral amygdaloid nucleus, dorsolateral part (LaDL), lateral amygdaloid nucleus, ventrolateral part (LaVL),
basolateral amygdaloid nucleus, anterior part (BLA), basolateral amygdaloid nucleus, ventral part (BLV), bed nucleus of the striater minalis, intra
amygdaloid (STIA), basomedial amygdaloid nucleus, anterior part (BMA), dorsal endopiriform nucleus (DEn), ventral endopiriform claustrum (VEn),
piriform cortex (Pir), lateral parabrachial nucleus (LPB), medial parabrachial nucleus (MPB), locus coeruleus (LC), barrington’s nucleus (Bar).
Abbreviations and described spinal cord regions; vertebrae lumbales 2 (L2), central canal (CC), intermediomedial column (IMM), lamina 7 of the
spinal gray (7Sp), lamina 8 of the spinal gray (8Sp), lamina 10 of the spinal gray (10Sp), axial muscle motoneurons of lamina 9 (Ax9), psoas
motoneurons of lamina 9 (Ps9). Bregma levels, and described brain and spinal cord regions according to Franklin and Paxinos 2007 [28] and Allen
Mouse Brain Atlas [29].
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Figure 4 (See legend on next page.)
Hägglund et al. BMC Neuroscience 2013, 14:54 Page 6 of 18
http://www.biomedcentral.com/1471-2202/14/54
(See figure on previous page.)
Figure 4 B0AT3 immunoreactivity in vesicles, GABAergic and other neurons. Immunohistochemistry on mouse brain and spinal cord with
B0AT3 immunoreactivity (red), markers (green), and nucleus marker DAPI (blue). (A) B0AT3 was extensively expressed in cortex (Bregma 0.02)
together with NeuN positive cells and found in the soma and axon (B) The neuronal marker MAP2 and B0AT3 were found together in cortex
(Bregma −0.70). (C) The immunoreactivity of the GABAergic marker Gad67 overlapped with the expression of the B0AT3 transporter in cortex
(Bregma −0.10). (D) Highly overlapping expression was seen for B0AT3 and the presynaptic GABAergic neuronal marker VIAAT in hippocampus
(Bregma −3.40). (E) Immunoreactivity of B0AT3 and the vesicular marker synaptophysin extensively overlapped in spinal cord (upper vertebrae L2
lumbar). (F) No overlap was seen with the astrocyte marker GFAP and B0AT3 in hypothalamus (Bregma −0.82). (G) No protein overlap was seen
between B0AT3 and pan-cytokeratin (Bregma −2.30, around the third ventricle). Confocal pictures on paraffin sections taken with 63x magnification.
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http://www.biomedcentral.com/1471-2202/14/54expression pattern was also seen in brain (Figure 4E). As
expected, the B0AT3 transporter did not co-localize with
the astrocyte marker GFAP [27] in hypothalamus or in
other areas of the brain (Figure 4F). Interestingly, the
choroid plexus epithelial cell marker pan-cytokeratin [35]
localized in cells surrounding the ventricles, towards the
cerebrospinal fluid (CSF), while B0AT3 was found in the
same cells but on the opposite side (Figure 4G). The pro-
tein expression of B0AT3 and pan-cytokeratin did not
overlap in the lateral ventricle (LV) or in any of the other
ventricles in brain. Additionally, markers for phosphate-
activated glutaminase (PAG), the enzyme which generates
glutamate and ammonia from glutamine [36,37], and ves-
icular glutamate transporters (VGLUT1 and VGLUT2)
[38-40] were used to investigate the expression of B0AT3
in excitatory neurons. Highly overlapping expression was
seen for B0AT3 and PAG in cortex and in cells close to
the 3 V in hypothalamus in the brain (Figure 5A). Moder-
ate overlapping expression was seen for VGLUT1 and
B0AT3 in the gray matter of dorsal horn in spinal cord
and in the brain (Figure 5B), while extensively overlapping
expression was seen for B0AT3 and VGLUT2 in gray mat-
ter of ventral horn in spinal cord and in the cortex in the
brain (Figure 5C). The VGLUT2 staining shown here indi-
cates synaptic staining as well as staining on the cell-
bodies, which should be interpreted with caution as this
is normally not seen and could be the result of non-
specific staining. Similar overlap was also seen between
VGLUT1 (Additional file 1: Figure S2A) as well as be-
tween VGLUT2 and B0AT3 (Additional file 1: Figure S2B)
in the brain. To conclude, B0AT3 is located on GABAergic
and glutamatergic neurons with expression in synapses in
the brain and in spinal cord.Protein interactions between B0AT3 and synaptic vesicles
and between B0AT3 and glutaminase
The proximity ligation assay (PLA) technology was used
for detection of interactions between antibodies targeting
B0AT3 and the vesicle marker (synaptophysin), and be-
tween B0AT3 and the glutaminase marker PAG in hypo-
thalamic mouse cells (Figure 5). No protein interactions
were seen in the negative control (Figure 5D). A moderate
number of interactions were seen between 0B0AT3 andsynaptophysin (Figure 5E), while a higher number of inter-
actions was seen between B0AT3 and PAG.Cellular localization of B0AT3 immunoreactivity in
neurons and synapses in primary cell culture
Immunohistochemistry was used to investigate neuronal
and vesicular localization of B0AT3 in mouse E13 primary
cell cultures (Figure 6). The immunoreactivity of B0AT3
and the neuronal marker microtubule-associated protein
2 (MAP2) [31] highly overlapped in the cell body close to
the membrane and in the dendrites of single cells from
whole brain (Figure 6A). Only cells containing large nuclei
were labelled with MAP2, while cells with smaller nuclei,
representing non-neuronal cells, were not labelled with
either the neuronal marker or B0AT3. In the next experi-
ment, cells were grown for longer time prior to immunohis-
tochemistry to be able to study the B0AT3 expression in
colonies of more matured cells. B0AT3 immunofluorescence
indicated expression in the neuronal axons on cells from
fore brain (Figure 6B). To further visualize the vesicular
localization of B0AT3 the vesicular marker synaptophysin
[34] was co-labelled with B0AT3 on cells from fore brain.
The B0AT3 and synaptophysin proteins were highly overlap-
ping in the cell bodies and in the axons.Up-regulation of Slc6a17 in hypothalamus in food
restricted rats
Changes in expression levels of Slc6a17 and Slc6a15 were
investigated in a model for appetite where rats were acutely
food deprived for 48 hours (short term starvation) or 45%
chronic food restricted during 12 days (long term starva-
tion) and compared with an ad libitum fed control group
(Figure 7A-B). Expression levels were studied in a number
of tissues; hippocampus, hypothalamus, periaqueductal
gray and prefrontal cortex. A significant (p = 0.0461) up-
regulation was seen for Slc6a17 in hypothalamus after
short term starvation, and a trend of up-regulation was
seen after long term starvation (Figure 7A). This suggests
that Slc6a17 has a more pronounced role in anticipation of
food than in appetite regulation. No significant differences
in expression were seen for Slc6a15 in any of the studied
tissues (Figure 7B), and no significant up-regulation was
seen for the Slc6a15 gene in food restricted rats.
Figure 5 (See legend on next page.)
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Figure 5 Protein localization and interactions of B0AT3 to glutamatergic neurons and vesicles. Immunohistochemistry (A-C) on mouse
brain and spinal cord and proximity ligation assay (PLA) (D-E) on a hypothalamic mouse cell line are illustrated here with B0AT3 immunoreactivity in
red, markers in green, and nucleus marker DAPI in blue. (A) Highly overlapping expression in glutamatergic neurons between B0AT3 and the enzyme
PAG in cerebral cortex in the brain (Bregma 1.18). (B) Low overlapping expression for the vesicular marker VGLUT1 and B0AT3 in dorsal horn in spinal
cord (upper vertebrae L2 lumbar). (C) Expression of the vesicular glutamate transporter VGLUT2 extensively overlapped with the expression of the
B0AT3 transporter in ventral horn in spinal cord (Bregma −0.10). Fluorescent micrographs of paraffin sections taken with 40x magnification. PLA signals
(red fluorescent amplification product) and the nuclei (blue) are shown as an increased intensity projection of the raw image based on 20 z-planes
(D-F). (D) No interactions were seen in the negative control that was run without primary antibodies. (E) Moderate number of interactions detected
between B0AT3 and synaptophysin. (F) High number of interactions detected between B0AT3 and PAG (scale bar, 10 μm).
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http://www.biomedcentral.com/1471-2202/14/54Up-regulation of Slc6a17 and Slc6a15 in rats treated with
antidepressant drugs
The monoamine system was challenged with antidepres-
sants to study the serotonin (fluoxetine) and the dopa-
mine/noradrenaline systems (bupropion) (Figure 7C-D).
Changes in mRNA expression of Slc6a17 and Slc6a15
transporters as response to the drugs were investigated in
a number of tissues (amygdala, brain stem, hippocampus,Figure 6 B0AT3 immunoreactivity co-localized with neuronal and ves
performed on embryonic mouse E13 primary cell cultures with B0AT3 antib
overlapping expression of B0AT3 and the neuronal marker MAP2 in the cel
whole brain. Large nucleus belong to neuronal cells labelled with MAP2, w
B0AT3 and MAP2 in neuronal axons on cells from fore brain. (C) Co-localiza
fore brain (scale bar, 10 μm).hypothalamus and prefrontal cortex). Slc6a17 was signifi-
cantly up-regulated in hippocampus independent of the
dose of fluoxetine (p = 0.0009), while a trend of up-
regulation was seen after bupropion treatment (Figure 7C).
Bupropion injection caused a significant up-regulation of
Slc6a17 in hypothalamus (p = 0.0002) and in prefrontal
cortex (p = 0.0005). No changes in gene expression were
seen in amygdala and brainstem. Interestingly, a similaricle markers in primary cell cultures. Immunohistochemistry was
ody (green), markers (red) and nucleus marker DAPI (blue). (A) Highly
l body close to the membrane and on dendrites in single cells from
hile small nucleus represent glial cells. (B) Overlapping expression of
tion of B0AT3 and the vesicular marker synapophysin on cells from
Figure 7 Changes in Slc6a17 expression levels in hypothalamus in overnight starved and long term food restricted (45% of ad lib food
intake), as well as in hippocampus and hypothalamus in a model for the monoamine system. (A-B) Three groups (n = 8 rats/group) were
compared within a control group with free access to food (dark grey), a food deprived group (white), and a food restricted group (light grey).
(A) In the restricted animals, the gene expression of Slc6a17 significantly (p = 0.0461) was up-regulated in hypothalamus. (B) The Slc6a15 gene
was not significantly up- or down-regulated in any of the studied tissues. (C-D) Four groups (n = 8 rats/group) were compared within a control
group given saline (dark gray), a group given 3 mg/kg fluoxetine (white), a group given 10 mg/kg fluoxetine (light grey) and a group given
25 mg/kg bupropion (black dots). (C) The Slc6a17 gene was significantly (p = 0.0009) up-regulated in hippocampus after low and high dose of
fluoxetine application, while a non significant up-regulation was seen after bupropion treatment. Bupropion injection caused a significant up-
regulation of Slc6a17 in hypothalamus (p = 0.0002) and in prefrontal cortex (p = 0.0005). (D) Significant (p = 0.0006) up-regulation of Slc6a15 was
seen in hippocampus after injection of both doses of fluoxetine and bupropion and the Slc6a15 gene was significantly (p = 0.0002) up-regulated
in prefrontal cortex after bupropion treatment. All data were normalized to the mean value for the control group. Significance levels were
obtained from one-way ANOVA followed by Tukey’s post hoc test on a data set with p < 0.05 from the ANOVA. Multiple comparison test
significant levels are indicated by asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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http://www.biomedcentral.com/1471-2202/14/54pattern was seen for the related Slc6a15 transporter,
with up-regulation in hippocampus after injection of
both doses of fluoxetine and the bupropion antidepressant
(p = 0.0006) (Figure 7D). The Slc6a15 gene was also
significantly up-regulated in prefrontal cortex after bupro-
pion treatment (p = 0.0002).
Discussion
In this study we used quantitative RT-PCR (qPCR) in a
large panel of adult rat brain and peripheral tissues
(Figure 1), to further refine the expression profile of the
Slc6a17 gene. The highest expression levels of Slc6a17
mRNA were found in hindbrain, various brain crosssections, cerebellum, spinal cord, brain stem and hypo-
thalamus, while very low or no expression was seen in
the peripheral tissues with the exception of epididymis.
Consequently, the Slc6a17 transporter is highly and se-
lectively expressed in the CNS of adult rat.
Abundant mRNA expression of Slc6a17 in adult and
embryonic rat CNS has previously been shown using in
situ hybridization. Consistent results indicated restricted
expression exclusively in neurons, both glutamatergic
and subsets of GABAergic [4,9,15-17]. Our results from
in situ hybridization (Figure 3) shows that the mouse
Slc6a17 gene has similar expression pattern as previ-
ously seen in rat, with high expression in mouse
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http://www.biomedcentral.com/1471-2202/14/54forebrain and midbrain and lower expression in some
parts of the hindbrain such as the basal ganglia. Low
mRNA expression was seen in spinal cord. We con-
firmed Slc6a17gene expression in GABAergic neurons
in hippocampus, in the pyramidal and granule cell layer
of the dentate gyrus [41], and in the Purkinje cell layer
of cerebellum [42]. The mRNA expression was also
found in all layers of cerebral cortex, except layer 1, with
strongest expression in cortical layer 5, results that sup-
port expression by glutamatergic neurons [43]. The layer-
like pattern in cortex gives strength to the conclusion that
the expression is neuronal, while a scattered pattern
would suggest expression in astrocytes. Hybridization in
sections of mouse spinal cord showed expression in sub-
sets of somatic motor neurons and in interneurons. Cor-
tical co-localization of Slc6a17 mRNA with glutamatergic
(PAG) and GABAergic (Gad67) mRNA markers con-
firmed Slc6a17 staining in both excitatory and inhibitory
neurons in brain (Figure 2), while co-immuno labeling
with the astrocyte protein marker GFAP showed no over-
lap in spinal cord, suggesting no expression of Slc6a17 in
glial cells. The expression in Piris is highly interesting as
this area have been shown to be part of a possible amino
acid chemo-sensing system, involved in recognition of di-
ets with deficiency of essential amino acids, producing an
anorectic response [44,45]. We also found expression of
Slc6a17 in many regions involved in homeostatic control,
with pronounced hypothalamic expression specifically in
VMH, DMH, LH and Arc. In addition, we found expres-
sion in the amygdala (BLA), the pons (LC), and the ventral
striatum (NAcc). These are all areas known to be part of
the reward network and in regulation of food intake
[46-49]. The Slc6a17 mRNA expression pattern in mouse
CNS strongly suggests that Slc6a17 play a role in both ex-
citatory and inhibitory neurotransmission and that the
transporter could be involved in regulating food intake.
Here, we used a custom-made mouse B0AT3 antibody
for further cellular localization of the B0AT3 protein in
mouse brain and spinal cord. Immunohistological double
labelling on primary cell cultures with the neuronal cell
marker (MAP2) and the neuronal terminal marker
(synaptophysin) visualized B0AT3 localization to neurons,
with expression both in soma and in synapses (Figure 6).
In addition, PLA studies showed protein proximity be-
tween antibodies targeting B0AT3 and synaptophysin, a
marker for synaptic vesicles, in a hypothalamic mouse cell
line (Figure 5). Localization to synapses was also con-
firmed with double labelling on mouse brain and spinal
cord sections (Figures 4 and 5). GABAergic markers
(GAD67 and VIAAT) were used and showed neuronal
B0AT3 localization in GABAergic neurons and in
GABAergic synapses. Interestingly, glutamatergic markers
(PAG, VGLUT1 and VGLUT2) showed that B0AT3 is also
localized at glutamatergic neurons and in glutamatergicsynapses. Direct protein interactions between B0AT3 and
PAG in glutamatergic neurons were shown with PLA. We
further investigated whether B0AT3 was expressed in
choroid plexus, by co-staining with pan-cytokeratin to
visualizethe cellular layer surrounding the ventricles of the
brain. Highly overlapping expression has previously been
shown for B0AT2 and the choroid plexus marker (unpub-
lished data), here B0AT3 and pan-cytokeratin did not co-
localize. Despite the absence of co-localization within
cells, B0AT3 still localized to the choroid plexus, but only
to the brain side of choroid plexus cells. Possibly, B0AT3
and B0AT2 function within these cells and contribute to
the uptake of circulating amino acids from the blood
stream into the brain. B0AT3 has been suggested to be
H+-dependent [11], but another study has shown that it is
Na+-dependent [12]. Our results, showing very clear ex-
pression in synapses (most likely located in vesicles), sup-
port that B0AT3 is H+-driven, a feature typical for other
vesicular transporters such as VGLUTs, VIAAT and
VMAT[38,50]. However, some IHC staining presented
here suggest that B0AT3 is also found in the soma of neu-
rons, most likely with expression in the plasma mem-
brane. If this expression is functionally relevant, B0AT3 is
most likely utilizing the Na+-gradient over the plasma
membrane to drive transport. This is supported by previ-
ous studies that have shown that, transport through
B0AT3 can be driven by H+ as well as Na+ gradients [12].
Both acute and chronic food restriction (Figure 7) in-
duce activation of synaptic neurotransmission in hypo-
thalamus, which in turn boasts a strong signal to start
food seeking and consumption. Starvation increases the
levels of circulating ghrelin which activates neurons in
hypothalamus to release the excitatory neurotransmitter
glutamate [51,52]. Glutamate can in turn activate the N-
methyl-D-aspartate (NMDA) receptor [53,54] located on
GABAergic neurons, also expressing NPY and AgRP,
and hence stimulate feeding [26]. Our results show that
Slc6a17mRNA is highly regulated in response to starva-
tion, suggesting that up-regulation of the transporter
could be part of the enhancement of the excitatory sig-
nal during starvation (Figure 7A), while the expression
of Slc6a15 appeared to be less affected. The effect was
only seen for long term food restriction, and was not ob-
served after acute food deprivation. Up-regulation of the
Slc6a17 transporter indicates increasing uptake of amino
acids into vesicles, a function that could influence a
number of other mechanisms. B0AT3 has a broad transport
profile displaying, among others, uptake of glycine. Of all
transporters of amino acids, there are a number of known
transporters, with high capacity for glycine transport (GlyT1
(SLC6A9), GlyT2 (SLC6A5), SNAT2 (SLC38A2), PAT1
(SLC36A1), VIAAT (SLC32A1) [3,50,55,56]), although only
B0AT3 has vesicular expression. Here, we also study the
mRNA expression of Slc6a17 in POMC and NPY positive
Hägglund et al. BMC Neuroscience 2013, 14:54 Page 12 of 18
http://www.biomedcentral.com/1471-2202/14/54cells. The Slc6a17 transporter showed localization both
at hypothalamic POMC and NPY neurons (Figure 2),
which is in agreement with the possible role in body
weight homeostasis.
When we challenged the 5-HT (fluoxetine) and the DA/
NA systems (bupropion) in rats over a treatment period
of fourteen days, we found significant changes in the levels
of transcripts for Slc6a17 and Slc6a15 (Figure 7C-D). Ad-
ministration of fluoxetine, an antidepressant of the select-
ive 5-HT reuptake inhibitor (SSRIs) type, resulted acutely
in an increase of 5-HT in the synaptic cleft. Both Slc6a17
and Slc6a15 were significantly up-regulated in hippocam-
pus after fluoxetine injections. Similar stimulatory effect
on hippocampal and cortex expression is observed for the
vesicular glutamate transporter VGLUT1 in response to
antidepressant treatment with fluoxetine, and the trans-
porter is linked to increased 5-HT levels [57,58]. More-
over, mice with reduced VGLUT1 expression show
increased anxiety, depressive-like behaviors, and impaired
recognition memory [59]. Bupropion acts as a dual NA
and DA uptake inhibitor in several mesocorticolimbic
areas [60]. The drug inhibit the reuptake of NA and DA
through blockage of the NA transporter (NET/SLC6A1)
and DA transporter (DAT/SLC6A3) in humans, without
affecting release or transport of other neurotransmitters
and without binding to other neurotransmitter receptors
[61]. We showed that increased levels of DA and NA gave
significant up-regulation of both Slc6a17 and Slc6a15 in
prefrontal cortex, up-regulation of Slc6a17 in hypothal-
amus and of Slc6a15 in hippocampus. The results once
again demonstrate that the expression levels of Slc6a17
and Slc6a15 are regulated by changes in monoamine
levels. We suggest that the increase of these transporters
may have a role in regulating the availability of amino
acids used for neurotransmitter precursors. The Slc6a15
results are supported by results from a previous study by
Kohli et al. [24] where SLC6A15 was associated with
major depression. Here it was found, in a whole genome
association study, that allelic variants of SLC6A15 in-
creased the risk of acquiring major depression, although
the mechanism behind this is not known. Antidepressant
drugs are thought to acutely increase the levels of 5-HT
and NA/DA in the brain but, in long term antidepressant
drugs, it has been shown to induce remodeling of neur-
onal circuits by strengthening of synapses [25], involving
both glutamatergic and GABAergic neurons and possibly
SLC6A15 and SLC6A17 could play a role in these long
term effects. It is also known that starvation induces
glutamatergic signaling in POMC neurons of the hypo-
thalamus and it is possible that B0AT3 enhances the sig-
naling capabilities of glutamatergic neurons. B0AT3 is
unique among the SLC6 family of proteins in that sense
that it is expressed on vesicles rather than on the plasma
membrane. B0AT3 has been shown to transport, amongother amino acids, glycine. Glycine has at least two im-
portant functions in glutamatergic neurotransmission;
first, glycine can be used for the synthesis of the excitatory
neurotransmitter glutamate, and secondly, glycine is a ne-
cessary co-factor for the ability of glutamate to activate
NMDA receptors [53,54,62]. The up-regulation of the
Slc6a17 transporter after long term food restriction and
activating drugs suggests the transporter to be involved in
the increased glutamatergic signaling. It is possible that
B0AT3 provides a mechanism to enhance NMDA receptor
activation, possibly providing stronger LTP response, by
packing glycine into glutamate containing vesicles and
hence increase the local concentration of glycine in the
synaptic cleft.
Conclusions
In conclusion we provide an extensive localization study
of B0AT3 (Slc6a17) in mouse nervous system. We show
that B0AT3 is expressed in both excitatory and inhibitory
neurons, with high expression in synapses, although we
also see expression in the somato-dendritic part of neu-
rons. We show that B0AT3 expression is highly overlap-
ping with VIAAT and VGLUT2 expression, and to a
lesser extent with VGLUT1. We also demonstrate that
Slc6a17mRNA is highly regulated by administration of
drugs targeting the 5-HT system and the dopamine and




All animal procedures were approved by the local ethical
committee in Uppsala and followed the guidelines of
European Communities Council Directive (86/609/EEC).
RT-PCR on a panel of rat tissues
Animal handling and tissue isolation
Four male and two female adult Sprague–Dawley rats
(Alab, Sweden) were kept under controlled environmen-
tal conditions (12 hour dark/light cycles, in an air hu-
midity of 55% at 22°C). The rats had ad libitum access
to water and R36 food pellets (Lactamin, Sweden). These
conditions were maintained for 7 days, and at the end of
the period the animals were sacrificed by decapitation
between 3 and 6 h into the light period. Various brain
regions and peripheral tissues (Figure 1) were isolated by
dissection and two brains were dissected into cross sec-
tions, termed I-VIII in Figure 1, using a brain matrix as
described in Lagerström et al. [63]. In short, the olfac-
tory bulb was removed in one piece before putting the
brain in the matrix (I). Slices (II-VII) were cut with razor
blades (approximately 3 mm thick), with an exception
for the last slice (VIII) which was slightly thinner. The
tissues were immersed into RNA-later solution (Ambion,
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after stored at −80°C until further processed.
RNA preparation and cDNA synthesis
Tissue samples were homogenized by ultra-sonication in
TRIzol reagent (Invitrogen, Sweden) using a sonicator
(Branson Ultrasonics Corporation, USA). Chloroform
was added to the homogenate, and samples were
centrifuged at 12000 g for 15 min at 4°C. The aqueous
phase was transferred to a new tube and isopropanol
was added for RNA precipitation. Samples were incu-
bated at −20°C over night, centrifuged at 12000 g for
10 min at 4°C to form pellets, which were washed with
75% ethanol, air dried and dissolved in RNAse-free
water. DNA contamination was removed by RNase-free
deoxyribonuclease 1 (Roche Diagnostics, Sweden) treat-
ment for 3 hours at 37°C. The RNA was confirmed to be
free of genomic DNA by PCR with rGapdh primers, for
primer information see Table 1. Total RNA concentra-
tion was determined using a NanoDrop ND-1000 spec-
trophotometer (NanoDrop Technologies, USA). For
cDNA synthesis, M-MLV reverse transcriptase (General
Electric, Sweden) was used with random hexamers as
primers according to manufacturer’s instructions. The
cDNA synthesis quality was then confirmed by PCR, as
described above.
Quantitative real-time PCR
The cDNA was analyzed with quantitative real-time PCR
on MyiQ (Bio-Rad Laboratories, USA). All primers were
designed with Beacon Designer v4.0 (Premier Biosoft,
USA). Primers used for housekeeping genes were H3f3b
and Rpl19 and Slc6a17 was the gene of interest (for pri-
mer information, see Table 1). Each real-time PCR reac-
tion had a total volume of 20 μl and contained cDNA
synthesized from 25 ng of total RNA; 0.25 μmol/ l of each
primer, 20 μmol/l Tris/HCl (pH 8.4), 50 μmol/l KCl,
4 μmol/l MgCl2, 0.2 μmol/l dNTP, SYBR Green (1:50000
dilution). Real-time PCR was performed with 0.02 u/μl
Taq DNA polymerase (Invitrogen, USA) under theTable 1 Primer information









Slc6a15 NM_172321 tgcatggatcaaggagaaggfollowing conditions: initial denaturation for 3 min at
95°C, followed by 50 cycles of 15 sec at 95°C, 15 sec at
51–54°C (optimal annealing temperature) and 30 sec at
72°C. This was followed by 84 cycles of 10 sec at 55°C
(increased by 0.5°C per cycle). All real-time PCR exper-
iments were performed in duplicates and measure-
ments with Δ threshold Ct-values larger than 0.99 were
repeated. A negative control (water) for each primer
pair and a positive control with 25 ng of rat genomic
DNA was included on each plate.
Data analysis and relative expression calculations
The MyIQ v1.04 software (Bio-Rad Laboratories,
Sweden) was used to analyze the real-time PCR melt
curve data and threshold cycle Ct-values. Melting curves
were compared to the positive (genomic DNA) and
negative (water) control to confirm that only one prod-
uct with the expected melting point was amplified and
that the product was different from the negative control.
The duplicates for the raw Ct-values were compared and
excluded if the differences was greater than 0.99. The
sample Ct-values were considered expressed and further
analyzed if the difference between the sample and the
negative control was greater than 2. LinRegPCR v7.5 [64]
was used to calculate PCR efficiencies for each sample.
The average PCR efficiency and standard deviation for the
primer pair was calculated after excluding outliers found
with Grubbs’ test (GraphPad, USA). The delta Ct-method
was used to transform the Ct-values into relative quantities
with standard deviations. Subsequently, all values were di-
vided by the relative quantity for genomic DNA and the
GeNorm software [65] was used on the two housekeeping
genes in order to calculate normalization factors for every
tissue and to compensate for differences in cDNA amount.
The gene of interest was normalized to the geometric
mean of the expression levels of the rH3f3b housekeeping
gene and the normalized quantities were then calculated to
the expression relative to maximum (fold decrease) by
assigning the tissue with the highest expression the value
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Tissue collection and sectioning
Tissue collection and sectioning of free floating and par-
affin embedded mouse brain and spinal cord sections
were performed as described previously [66], with the
exception that mice were anesthetized with an intra-
peritoneal injection of sodium pentobarbital (90 mg/kg
IP; Apoteksbolaget, Sweden) instead of Ketalar and
Domitor. Cryo sections were made with fresh frozen
mouse brains. Animals were sacrificed by decapitation and
the brains were rapidly removed and frozen in 2-methyl
-butane at −25 ± 5°C and kept at −80°C until further pro-
cessing. Coronal frozen sections (14 μm) were cut using a
Leica CM1800 cryostat (Leica Microsystems, Germany)
at −20 ± 1°C, thaw-mounted on gelatin-coated slides and
dried with a fan for 60 min before storage at −80°C.
Design and synthesis of RNA probes
Antisense probes were generated from commercial mouse
cDNA clones (Invitrogen, USA) by using gene-specific
promoters, described in Table 2. The clones were se-
quenced (Eurofins MWG Operon, Germany) and verified
to be correct. The plasmids were linearized with restric-
tion enzymes (Fermentas, Canada) as detailed in Table 2,
and the probes were synthesized using 1 μg cleaved vector
as template with T7 or T3 RNA polymerases in the pres-
ence of digoxigenin (DIG)- or fluorescein (FITC)-11-UTP
(Roche Diagnostics, Switzerland). Labeled probes were
quantified using the NanoDrop ND-1000 spectrophotom-
eter (NanoDrop Technologies, USA).
Double in situ hybridization on cryo sections
Day 1, sections were rinsed in PBS, digested in protein-
ase K and fixed in 4% PFA. After washes in PBS, sections
were acetylated in 1.3% trietholamine (Sigma-Aldrich,
USA), 0.06% HCl (Sigma-Aldrich, USA), and 2% acetic
anhydride (Fluka, Switzerland) diluted in 0.1% DEPC
water. Sections were then permeabilized in 1% Triton X-
100 and rinsed in PBS prior pre-hybridized in hybridization
buffer (50% formamide (Sigma-Aldrich, USA), 5XSSC,
pH 4.5, 5XDenhardt’s solution, 250 μg/ml of yeast transfer
RNA (Sigma-Aldrich, USA), 500 μg/ml of sheared salmon
sperm DNA (Ambion, USA) in 0.1% DEPC water) for
2 hours at 55°C. DIG-labeled Slc6a17 and FITC-labeled
POMC or NPY were denatured and added (0.8 μg/150 μl)Table 2 Details of in situ hybridization probes





Gad67 6808909 2680-3153for hybridization overnight at 55°C. Day 2, sections were
rinsed in warm 5XSSC, incubated in 0.2XSSC for 1 hour at
55°C, washed in 0.2XSSC, and pre-blocked in blocking so-
lution (0.1 M Tris–HCl, pH 7.5, 0.15 M NaCl, and 10% al-
bumin bovine serum (Sigma-Aldrich, USA)) for 1 hour.
Then, sections were incubated in alkaline phosphatase
(AP) anti-DIG Fab fragments (1:5000, Roche Diagnostics,
Switzerland) diluted in blocking solution overnight. On
day 3, sections were washed in TBST with 2 mM levami-
sole and subsequently in NTMT with 2 mM levamisole,
thereafter color was developed in Fast Red solution (Roche
Diagnostics, Switzerland). Sections were treated with
5XSSC for 1 hour at 55°C and incubated in glycine-HCl
for 30 min to inactivate the alkaline phosphatase. After
rinsing in PBS sections were pre-blocked before incubation
overnight in anti-FITC-AP Fab fragments (1:5000,
Roche Diagnostics, Switzerland) diluted in blocking so-
lution. On day 4, color development was performed
with BM-Purple-AP enzyme substrate (Roche Diagnostics,
Switzerland) at 37°C. Sections were mounted in 50% gly-
cerol and analyzed using a microscope (Olympus, Japan)
with an Optigrid system (Thales Optem,USA) and
Volocity software (Improvision, USA).
Double in situ hybridization on paraffin sections
The method was performed as described for “combined
in situ hybridization/immunohistochemistry on paraffin
sections” previously described in [66], with the following
exceptions: Day 1 - DIG-labeled Slc6a17 and FITC-
labeled Glutaminase or Gad67 were denatured and
added (0.8 μg/150 μl) for hybridization. Day 2 - incuba-
tion in anti-FITC-POD Fab fragments (1:500, Roche
Diagnostics, Switzerland). Day 3 - DAB (Sigma-Aldrich,
USA) substrate was developed and sections were incu-
bated in anti-DIG-AP Fab fragments (1:5000, Roche
Diagnostics, Switzerland). Day 4 - Fast Red (Roche Diag-
nostics, Switzerland) was developed.
Combined in situ hybridization/immunohistochemistry on
paraffin sections
The method was performed as described previously in
[66], with some exceptions. The DIG-labeled Slc6a17
probe was detected with BM-Purple-AP substrate en-
zyme, while the glial fibrillary acidic protein (GFAP) was
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respectively).
In situ hybridization on free floating sections
Single probe in situ hybridization was performed on free
floating mouse brain and spinal cord sections as described
previously [66], with some exceptions. The hybridization
was performed using 1 μg/ml DIG-labeled Slc6a17 probe di-
luted in hybridization buffer. Sections were mounted in 50%
glycerol and photographed using a Pannoramic midi scan-
ner and the Pannoramic viewer software v.1.14 (3DHistech,
Hungary).
Fluorescent immunohistochemistry on paraffin
embeddedsections
The method was performed as described previously in
[66], with some exceptions. Sections were incubated with
the custom-made polyclonal antibody rabbit-anti-B0AT3
(directed against the peptide sequence Ac-ELDTEDRPA
WNSKLC-CONH2, Innovagen, Sweden) together with
one of the antibody markers (NeuN, MAP2, Gad67, VIAAT,
synaptophysin, GFAP, pan-cytoceratin, PAG, VGLUT1,
VGLUT2) diluted in supermix (for antibody information





B0AT3 Rabbit 1:200 Custom made (Innovagen,
Sweden)
B0AT3 Mouse 1:50 Sigma-Aldrich, USA
NeuN Mouse 1:400 Millipore, Sweden
MAP2 Mouse 1:500 Sigma-Aldrich, USA
Gad67 Mouse 1:200 Millipore, Sweden
VIAAT Mouse 1:300 Synaptic Systems, Germany
Synaptophysin Mouse 1:200 BD Transduction lab,
Sweden
GFAP Chicken 1:400 AbCam, United Kingdom
Pan-cytokeratin Mouse 1:200 Sigma-Aldrich, USA
PAG Mouse 1:100 AbCam, United Kingdom
VGLUT1 Guinea pig 1:500 Innovagen, Sweden, based
on sequences described in
[40,67].
VGLUT2 Guinea pig 1:500 Innovagen, Sweden, based





Anti-rabbit-594 Donkey 1:400 Invitrogen, USA
Anti-guinea pig-488 Goat 1:400 Invitrogen, USA
Anti-mouse-488 Goat 1:400 Invitrogen, USA
Anti-chicken-488 Goat 1:400 Invitrogen, USALSM 510 Meta confocal microscope and analyzed with
AxioVision Rel. 4.8 software (Zeiss, Germany) or with a
fluorescent microscope (Zeiss Axioplan2 imaging) connected
to a camera (AxioCamHRm) with the Carl Zeiss AxioVision
v. 4.7 software.
Primary cell cultures
Tissue and cell collection
Primary forebrain cell cultures were prepared from em-
bryonic gestation day 13 (E13) mouse embryos. A preg-
nant female C57Bl6/J mouse was sacrificed by an
overdose of CO2. The uterus was surgically removed
from the mouse and placed in a petri dish with cold
Leibovitz’s L-15 medium (Invitrogen, USA). Forebrain
were isolated from embryos and transferred to a new
dish containing sterile L-15 medium and kept on ice.
Tissues were rinsed from meninges and cut into small
segments. The suspension was pipetted up and down in
a tip to further separate the tissue until a homogenous
solution was obtained. Homogenous solution was ap-
plied to a cell strainer (mesh size 70 μm) for filtration to
further dissociate cells and to remove large residue and
debris. Dissociated cells in solution were centrifuged at
1000 rpm for 5 min. The media was removed and the
pellets were resuspended in 10 ml Neurobasal medium
(Invitrogen, USA). Poly-L-lysine (10 μg/ml, Sigma-
Aldrich, USA) coated coverslips were added to the bot-
tom of a 12 well plate. Cells were plated in the wells at
an approximate density of 0.5 million cells/cm2, and in-
cubated at 37°C with 5% CO2 and 92% humidity. Cell
cultures were kept for 5–7 days in order for the cells to
mature.
Immunohistochemistry on primary cultures
Cells were rinsed in PBS, fixated in 4% PFA, pre-blocked
in supermix (Tris-buffered saline, 0.25% gelatin, 0.5%
Triton X-100), and incubated with the primary anti-
bodies B0AT3, MAP2, and synaptophysin diluted in
supermix over night at 4°C (for antibody information,
see Table 3). Cells were repeatedly rinsed in PBS, incu-
bated in secondary antibodies for 2 hours, and stained
with DAPI (1:2500) (Sigma-Aldrich, USA). After mount-
ing in glycerol with anti-fade (diazabicyclo, 2.2.2) octane,
images were captured on a Olympus BX61WI micro-
scope and analyzed with Volocity software (Improvision,
England), or z-stack pictures were taken on a Zeiss LSM
510 Meta confocal microscope and analyzed with
AxioVision Rel. 4.8 software (Zeiss, Germany).
Proximity ligation assay (PLA) technology
The immortalized embryonic mouse hypothalamus cell
line N25/2 (mHypoE-N25/2, Cellutions Biosystems Inc.,
Canada) was cultured on glass slides (coated with 10 μg/ml
poly-L-lycine) for 40 hours. Cells were rinsed with PBS and
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15 min. The Duolink II fluorescence kit (red detection re-
agents, Olink Biosciences, Sweden) was used to run in situ
proximity ligation assay (PLA) on the fixed cells according
to manufacturer’s instructions [68-71]. Information about
primary B0AT3, PAG and synaptophysin antibodies is
listed in Table 3. A negative control was run without pri-
mary antibodies. Protein interactions were detected with
anti-rabbit PLUS and anti-mouse MINUS PLA probes.
Slides were photographed using a fluorescent micro-
scope (Zeiss Axioplan2 imaging) connected to a camera
(AxioCamHRm) with the AxioVision v. 4.7 software (Carl
Zeiss, Germany). PLA signals were shown as a merged
image of the raw data aquired from 20 z-planes, using the
Axioplane software.
RT-PCR on tissues from food restricted rats and
antidepressant drugs- treated rats
Animal handling and tissue isolation, food restriction
Animals used in Lindblom et al. [72] were also used in
this study. Briefly, twenty-four male Sprague–Dawley
rats (Alab, Sweden) with initial body weight of 223 ±
1.5 g were randomized into control, food deprived and
food restricted groups (n = 8/group). The experiment
was maintained for 12 days and all animals had free ac-
cess to water. Food consumption was monitored daily
and body weights were measured every fourth day. Rats
in the control group had ad libitum access to R36 food
pellets (Labfor, Lactamin, Sweden), whereas, the food re-
stricted group received 45 ± 1% of the amount consumed
by the control animals. Food deprived animals had ad
libitum access to food until the last 48 hours of the ex-
periment, when they were completely deprived of food.
The experiment was maintained for 12 days and during
this period the control animals gained 40 ± 1.5% in body
weight, whereas the food restricted animals lost 8 ± 0.9%.
The deprived rats gained in total 24 ± 0.8% in body
weight. Animals were killed by decapitation, the brains
were rapidly removed and tissues of interest were iso-
lated by micro-dissection from slices obtained with a
brain matrix. Samples were rapidly frozen on dry ice,
immersed in RNA-later solution (Ambion, USA), kept at
room temperature for 1 hour and then stored at −80°C
until further processed.
Animal handling and tissue isolation, drug treatment
Thirty-two male Wistar rats were kept under controlled
environment with ad libitum access to R36 food pellets
and water. Rats were randomized into a saline control
group, two fluoxetine groups, one low dose (3 mg/kg) and
one high dose (10 mg/kg), and a high dose (25 mg/kg) bu-
propion group (n = 8/group). The antidepressants were
dissolved in saline. Animals were subcutaneously injected
with the drug once daily and the experiment weremaintained for fourteen days. Animals were decapitated,
brains were removed and tissues of interest were isolated
by micro-dissection from slices obtained with a brain
matrix. Samples were rapidly frozen on dry ice, immersed
in RNA-later solution (Ambion, USA), kept at room
temperature for 1 hour and then stored at −80°C until fur-
ther processed.
RNA preparation, cDNA synthesis and real-time PCR
RNA was extracted and converted into cDNA and used
as template for quantitative real-time PCR as described
in “RT-PCR on panel of rat tissues”. Primers used as
housekeeping gene was rCyclo, rH3f3b, rActb, rTubb5,
rRpl19, rGapdh and rSdha for food restricted rats and
the same set with the exclusion of rSdha for drug treated
rats (for primer information, see Table 1).
Data analysis and relative expression calculations
The MyIQ v1.04 software (Bio-Rad Laboratories,
Sweden) was used to analyze the real-time PCR melt
curve data and threshold cycle Ct-values. Melting curves
were compared to the positive (genomic DNA) and
negative (water) control to confirm that only one prod-
uct was amplified, with the expected melting point, and
that the product was different from the negative control.
The duplicates for the raw Ct-values were compared and
excluded if the differences were greater than 0.99. The
sample Ct-values were considered expressed and further
analyzed if the difference between the sample and the
negative control was greater than 2. LinRegPCR v7.5
[64] was used to calculate PCR efficiencies for each sam-
ple. The average PCR efficiency and standard deviation
for each primer pair were calculated after excluding out-
liers found with Grubbs’ test (GraphPad, USA). The
delta Ct-method was used to transform the Ct-values
into relative quantities with standard deviations. The
GeNorm software [65] was used on the housekeeping
genes in order to identify the most stable housekeeping
genes and to calculate normalization factors for each tis-
sue. The genes of interest were subsequently normalized
with the normalization factors obtained from GeNorm
and used for statistical analysis.
Differences in gene expression between groups were an-
alyzed using one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison post hoc test in
Prism v. 5.02 (GraphPad, USA) where appropriate p < 0.05
(95% confidence intervals) was used as criteria for statis-
tical significance for the ANOVA.
Additional file
Additional file 1: Figure S1. Characterization of the B0AT3 antibody.
The antibody specificity was investigated by immunohistochemistry on
mouse CNS tissues. Double immunohistochemistry with the custom
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http://www.biomedcentral.com/1471-2202/14/54made polyclonal B0AT3 antibody made in rabbit (red) and the
commercial available B0AT3 antibody made in mouse (green) on brain
(row A) and spinal cord (row B) tissue. The cell nucleus marker DAPI was
stained in blue. (A) Co-localization of B0AT3 antibodies in cells in cerebral
cortex in brain (Bregma -1.06). (B) Co-localization of B0AT3 antibodies in
motor neurons and other cells in spinal cord (L2). Scale bar: 10 μm. The
immunohistochemistry indicated that the custom made polyclonal B0AT3
antibody was epitope specific. Figure S2. Protein localization of B0AT3 to
glutamatergic neurons and vesicles. Red staining is B0AT3, green staining
is VGLUT1 and VGLUT2 respectively and blue is DAPI. (A) Overlapping
expression between B0AT3 and VGLUT1 in cerebral cortex in the brain.
(B) Overlapping expression for the vesicular marker VGLUT2 and B0AT3 in
in cerebral cortex in the brain. Table S1. CNS expression of Slc6a17
mRNA in mouse brain. The scale of estimated Slc6a17 mRNA expression
in the table; (+++) high expression, (++) medium expression, (+) low
expression, and (-) not detected.
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